-
Previous
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
$595.00 – $3,195.00
-
Next
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
$995.00 – $2,995.00
DT-061 (SMAP) Liposomes, Formulation TT-40
$995.00 – $2,995.00
PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.
Available Options:
Specifications
Product Data:
Figure 1 (Thumbnail). Enhancement of solubility for DT-061 is shown in the representative images. DT-061 is insoluble in aqueous media at the specified concentration (4.0 mg/mL). Matched concentration of DT-061 liposomes is shown.
Figure 2. DLS analysis of DT-061 Liposomes, Formulation TT-40 (batch 15304). The average size and PDI of triplicate measurements are annotated on the representative snapshot from DLS data acquisition screen. The data are representative of a typical batch.
DLL-0010 |
|
Encapsulated Compound | DT-061 |
Alias(es) | SMAP |
Target | PP2A (Protein Phosphatase 2 Catalytic Subunit Alpha) |
Activity | Activator |
Signaling Pathway | PP2A pathway (regulates MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis. cell cycle, and other pathways) |
TT-40 | |
4.0 mg/mL | |
60 mM | |
Hydration Solution | 300 mM sucrose |
External Solution | 300 mM sucrose |
Average Size | 70-120 nm |
Additional Information
Additional Information
Liquid, suspension | |
2 °C to 8 °C (do not freeze) | |
Shelf Life* | At least 1 month |
Applications | |
Background | |
References |
*Product is too new for long-term stability data. This section will be updated regularly as new data becomes available.